A phase 2/3 study of AGEN1181 in combination with balstilimab for the treatment of Cancer
Latest Information Update: 22 Mar 2021
At a glance
- Drugs Balstilimab (Primary) ; Botensilimab (Primary)
- Indications Colorectal cancer; Gynaecological cancer; Lung cancer; Malignant melanoma; Solid tumours
- Focus Therapeutic Use
- Sponsors Agenus
- 15 Mar 2021 Status changed from planning to recruiting, according to an Agenus media release.
- 09 Feb 2021 According to an Agenus media release, this study is scheduled to commence shortly.
- 10 Dec 2020 New trial record